schizophrenia
-
Artificial Intelligence, BioPharma
Sumitomo Schizophrenia Drug Discovered With AI Tech Fails in Two Phase 3 Trials
A schizophrenia drug candidate from partners Sumitomo Pharma and Otsuka Pharmaceutical failed to outperform a placebo in two Phase 3 studies. The compound is the most advanced program from a psychiatry and neurology collaboration spanning four drugs discovered by an artificial intelligence technology platform.
-
Neuro drugs dumped by AbbVie are now heading to Neurocrine for $100M up front
AbbVie returned the rights to the drugs to Sosei Heptares earlier this year. Now Neurocrine Biosciences has agreed to pay the Japanese drug company $100 million to license the rights to these preclinical and clinical-stage compounds that address muscarinic receptors to potentially treat a range of neurological disorders.
-
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
-
The emerging golden era of neuroscience
Bill Martin, the Global Therapeutic Area Head of Neuroscience at The Janssen Pharmaceutical Companies of Johnson & Johnson, shared some of the promising developments in the neuroscience space, such as the rise of neuro-immunology and the industry’s embrace of digital health tools to support drug development in a recent interview.
-
Bouncing back from FDA rejection, Alkermes psychiatric drug wins approval
Alkermes antipsychotic drug Lybalvi now has FDA approval. Though the field of neuropsychiatric drugs is crowded with generic medications, Alkermes believes Lybalvi, designed to mitigate the weight gain side effect common with mood disorder drugs, could have an advantage.
-
Intra-Cellular share price drops after FDA cancels expert panel meeting for schizophrenia drug
The company said the decision to cancel the advisory committee meeting for lumateperone was made so the agency would have additional time to review information the firm had provided regarding the drug.
-
Acadia Pharmaceuticals drug flops in Phase III schizophrenia study
Nuplazid, which is FDA-approved for Parkinson’s psychosis, failed to fully improve symptoms as an adjunctive treatment for schizophrenia.
-
Alkermes’ schizophrenia drug shows lower weight gain than comparator
The company plans to file a New Drug Application next year. An analyst wrote that it’s unclear if the drug will require review by an advisory committee.
-
Bain invests $350M in new company Cerevel to develop Pfizer’s neuroscience pipeline
Cerevel will take on several clinical and preclinical candidates from Pfizer, which divested from neuroscience this year and will take a 25 percent stake in the new company.
-
Otsuka, Proteus expand agreement around digital medicines
Otsuka also made an $88 million investment as part of the expansion. The companies plan to launch Abilify MyCite, approved in November 2017, by the end of this year.
-
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
-
System1 Biosciences raises $25M in Series A round for neurotherapeutics discovery platform
System1 Biosciences’ platform combines stem cell lines from patients with brain diseases with a three-dimensional in vitro system and data analytics.
-
Karuna Pharmaceuticals raises $42 million in Series A funding round
The company plans to use the financing to support development of its drug, KarXT, in schizophrenia and indications like pain.
-
Novartis teams up with Pear Therapeutics to develop digital therapeutics for schizophrenia, MS
Pear Therapeutics Chief Medical Officer Yuri Maricich emphasized that the products Pear is developing with Novartis are intended to do more than support adherence.
-
Hopkins, Salk seek new treatments for schizophrenia, bipolar disorder
The consortium will use induced pluripotent stem cell (iPSC) technology — a type of stem cell that can be generated from adult stem cells — to find better treatments for the two psychiatric conditions.
-
Memotext launches spinoff A4i that will call J&J’s Toronto innovation lab home
Memotext also embarked on a deal with Centre for Addiction and Mental Health in Canada to develop and commercialize a mobile health intervention for people with schizophrenia.
-
Alkermes gets FDA approval for monthly schizophrenia drug
Schizophrenia medication treatment could become easier and more effective with Alkermes’ FDA approval for Aristada.